MTEM
MTEM Real Time Price USDRecent trades of MTEM by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by MTEM's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
MTEM Revenue by Segment or Geography
New patents grants
-
Patent Title: Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector Dec. 31, 2024
-
Patent Title: Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors Dec. 31, 2024
-
Patent Title: De-immunized shiga toxin a subunit effector polypeptides for applications in mammals Aug. 20, 2024
-
Patent Title: Mhc class i epitope delivering polypeptides Jul. 16, 2024
-
Patent Title: Pd-l1-binding molecules comprising shiga toxin a subunit scaffolds Mar. 05, 2024
-
Patent Title: Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation Jan. 02, 2024
-
Patent Title: Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes Aug. 09, 2022
-
Patent Title: Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation Jul. 19, 2022
-
Patent Title: De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same Jun. 21, 2022
-
Patent Title: Mhc class i epitope delivering polypeptides Apr. 26, 2022
-
Patent Title: Multivalent cd20-binding molecule comprising shiga toxin a subunit effector polypeptides and enriched compositions thereof Feb. 15, 2022
-
Patent Title: Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds Jan. 18, 2022
-
Patent Title: Cd20-binding proteins comprising shiga toxin a subunit effector regions for inducing cellular internalization and methods using same Oct. 12, 2021
-
Patent Title: Pd-l1 -binding molecules comprising shiga toxin a subunit scaffolds Oct. 05, 2021
-
Patent Title: Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof Aug. 31, 2021
-
Patent Title: Cell-targeting molecules comprising protease-cleavage resistant, shiga toxin a subunit effector polypeptides and carboxy-terminal moieties Oct. 27, 2020
-
Patent Title: Predictive biomarker for hypoxia-activated prodrug therapy Sep. 01, 2020
-
Patent Title: Aziridine containing dna alkylating agents Jun. 02, 2020
-
Patent Title: Th-302 solid forms and methods related thereto May. 19, 2020
-
Patent Title: Cd20-binding immunotoxins for inducing cellular internalization and methods using same Oct. 22, 2019
-
Patent Title: Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity Sep. 24, 2019
-
Patent Title: Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof Aug. 27, 2019
-
Patent Title: Th-302 solid forms and methods related thereto Nov. 20, 2018
-
Patent Title: Predictive biomarker for hypoxia-activated prodrug therapy Sep. 11, 2018
-
Patent Title: Cytotoxic heteromeric protein combinatorial libraries May. 11, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to MTEM
Recent picks made for MTEM stock on CNBC
ETFs with the largest estimated holdings in MTEM
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $MTEM stock a Buy, Sell, or Hold?
- What is the price target for $MTEM stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $MTEM stock?
- Who owns the most shares of $MTEM stock?
- What funds own $MTEM stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MTEM Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.